ios ), ▁" life ". ▁The ▁term ▁" ant ib acter ial " ▁der ives ▁from ▁Greek ▁ ἀ ν τ ί ▁( anti ), ▁" ag ain st " ▁+ ▁ β α κ τ ή ρ ι ο ν ▁( b akt ē r ion ), ▁dimin utive ▁of ▁ β α κ τ η ρ ί α ▁( b akt ē ria ), ▁" st aff , ▁can e ", ▁because ▁the ▁first ▁b acter ia ▁to ▁be ▁discovered ▁were ▁rod - sh aped . ▁ ▁Research ▁ ▁Altern atives ▁The ▁increase ▁in ▁b acter ial ▁stra ins ▁that ▁are ▁resist ant ▁to ▁conventional ▁ant ib acter ial ▁ther ap ies ▁together ▁with ▁decre asing ▁number ▁of ▁new ▁ant ib iot ics ▁currently ▁being ▁developed ▁in ▁the ▁drug ▁pipeline ▁has ▁prompt ed ▁the ▁development ▁of ▁b acter ial ▁disease ▁treatment ▁strateg ies ▁that ▁are ▁alternatives ▁to ▁conventional ▁ant ib acter ial s . ▁Non - comp ound ▁approaches ▁( that ▁is , ▁products ▁other ▁than ▁classical ▁ant ib acter ial ▁agents ) ▁that ▁target ▁b acter ia ▁or ▁approaches ▁that ▁target ▁the ▁host ▁including ▁ph age ▁ther apy ▁and ▁v acc ines ▁are ▁also ▁being ▁investig ated ▁to ▁combat ▁the ▁problem . ▁ ▁Res istance ▁and ▁modifying ▁agents ▁ ▁One ▁strategy ▁to ▁address ▁b acter ial ▁drug ▁resistance ▁is ▁the ▁discovery ▁and ▁application ▁of ▁comp ounds ▁that ▁modify ▁resistance ▁to ▁common ▁ant ib acter ial s . ▁Res istance ▁modifying ▁agents ▁are ▁capable ▁of ▁partly ▁or ▁completely ▁suppress ing ▁b